

ExpreS2ion to Present in Upcoming Investor Events

Hørsholm, Denmark, 15 August 2025 – ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in August 2025: the presentation of Half-Year (Q2) results, Økonomisk Ugebrev's Life Science Investor Conference, and ProHearings' Capital Markets Day.

These events represent important opportunities to showcase ExpreS2ion's innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the [Company's website](#) and via the links below. To arrange a meeting at either event, please contact us at info@expreS2ionbio.com.

21 August 2025 | Presentation of 2025 Half-Year (Q2) Results

Virtual Webinar

CEO Bent Frandsen and CFO Keith Alexander will present ExpreS2ion's Half-Year (Q2) 2025 Report at a live virtual event hosted by H.C. Andersen Capital on Thursday 21 August 2025 at 10:30 CET. The event is open to all and free to attend. Registration is now available, and participants are encouraged to submit questions in advance via the email below. Register and join here: <https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-half-year-2025-report>

27 August 2025 | Økonomisk Ugebrev Life Science Investor Conference

Copenhagen, Denmark

Join us for a live presentation from our CEO Bent Frandsen on Wednesday 27 August at Økonomisk Ugebrev's Investor Conference hosted at Symbion in Copenhagen.

Registration is now open—tickets are free but must be booked in advance. Register here:

<https://konferencer.ugebrev.dk/event/investor-konference-den-27-august/>

29 August 2025 | ProHearings Capital Markets Day

Stockholm, Sweden

Join our CEO Bent Frandsen on Friday 29 August at ProHearings' Capital Markets Day in Stockholm's Hotel Birger Jarl. The event is a hybrid format – presentations are streamed live through ProHearings' platform, and registration is available for both in-person and virtual attendance. More information and registration: <https://www.prohearings.com/for-investors>

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO

Keith Alexander, CFO

E-mail: investor@expreS2ionbio.com

About ExpreS2ion

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expreS2ionbio.com.